Your browser doesn't support javascript.
loading
Measuring clinical utility in the context of genetic testing: a scoping review.
Walcott, Shantel E; Miller, Fiona A; Dunsmore, Kourtney; Lazor, Tanya; Feldman, Brian M; Hayeems, Robin Z.
Afiliação
  • Walcott SE; Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Miller FA; Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Dunsmore K; Toronto Health Economics and Technology Assessment, Toronto, ON, Canada.
  • Lazor T; Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Feldman BM; Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Hayeems RZ; Institute of Health Policy Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Eur J Hum Genet ; 29(3): 378-386, 2021 03.
Article em En | MEDLINE | ID: mdl-33087880
ABSTRACT
Standardized approaches to measuring clinical utility will enable more robust evaluations of genetic tests. To characterize how clinical utility has been measured, this scoping review examined outcomes used to operationalize this concept in the context of genetic testing, spanning relevant literature (2015-2017). The search strategy and analysis were guided by the Fryback and Thornbury hierarchical model of efficacy (FT Model). Through searches in Ovid MEDLINE, EMBASE and Web of Science, 194 publications were identified for inclusion. Two coders reviewed titles, abstracts, and full texts to determine eligibility. Results were analyzed using thematic and frequency analyses. This review generated a catalog of outcomes mapped to the efficacy domains of the FT Model. The degree of representation observed in each domain varied by the clinical purpose and clinical indication of genetic testing. Diagnostic accuracy (68%), technical (28.4%), and patient outcome (28.4%) efficacy studies were represented at the highest rate. Findings suggest that the FT Model is suitable for the genetics context however domain refinements may be warranted. More diverse clinical settings, robust study designs, and novel strategies for measuring clinical utility are needed.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article